Get the Stockscreener App
11.43
1.97%
-0.23
After Hours:
11.10
-0.33
-2.89%
89 Bio Inc stock is traded at $11.43, with a volume of 1.30M.
It is down -1.97% in the last 24 hours and up +46.16% over the past month.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
See More
Previous Close:
$11.66
Open:
$11.65
24h Volume:
1.30M
Relative Volume:
0.68
Market Cap:
$1.64B
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
-5.802
EPS:
-1.97
Net Cash Flow:
$-165.54M
1W Performance:
+18.57%
1M Performance:
+46.16%
6M Performance:
+43.95%
1Y Performance:
+40.59%
1-Day Range:
$11.33
$11.83
1-Week Range:
$9.16
$11.84
52-Week Range:
$5.9857
$16.63
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
142 SANSOME STREET, SAN FRANCISCO, CA
Compare ETNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
11.43 | 1.64B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Resumed | BofA Securities | Buy |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-10-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-23 | Initiated | UBS | Buy |
| Jun-13-23 | Initiated | Evercore ISI | Outperform |
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside 89bio's Latest Executive Compensation Move: 163K Share Options Granted - StockTitan
89bio (NASDAQ:ETNB) Stock Price Up 7.1%Here's What Happened - MarketBeat
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership - Yahoo Finance
SG Americas Securities LLC Has $284,000 Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Wolfe Research Initiates Coverage on 89bio (NASDAQ:ETNB) - Defense World
What is Leerink Partnrs’ Forecast for 89bio FY2024 Earnings? - Defense World
89bio Inc [ETNB] gain 37.47% so far this year. What now? - The DBT News
89bio Inc (ETNB)’s Market Momentum: Closing Strong at 10.75, Up 15.72 - The Dwinnex
FY2024 Earnings Estimate for 89bio Issued By Leerink Partnrs - MarketBeat
What is Leerink Partnrs’ Estimate for 89bio FY2029 Earnings? - Defense World
Wolfe Research Initiates Coverage of 89bio (ETNB) with Outperform Recommendation - MSN
89bio CEO awarded 200,000 restricted stock units By Investing.com - Investing.com Australia
Ra Capital Management, L.P. Acquires 5,714,285 Shares of 89bio, Inc. (NASDAQ:ETNB) Stock - MarketBeat
89bio CEO awarded 200,000 restricted stock units - MSN
89bio Inc (NASDAQ: ETNB) Is Expected To Soar To Higher Prices In The Months To Come. - Marketing Sentinel
ETNB’s Financial Health: Exploring 89bio Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet - MSN
FY2029 Earnings Forecast for 89bio Issued By Leerink Partnrs - MarketBeat
ETNB Insider Trade Alert! Majority Shareholder Sells $50M Worth of 89bio Stock - TipRanks
Short Interest in 89bio, Inc. (NASDAQ:ETNB) Grows By 12.2% - MarketBeat
89bio (NASDAQ:ETNB) Price Target Raised to $38.00 - MarketBeat
89bio (NASDAQ:ETNB) Receives Sell (D-) Rating from Weiss Ratings - Defense World
89bio Stock Upgraded to Buy: Positive SYMMETRY Study Data Reinforces FGF21 Analog Potential - TipRanks
RA CAPITAL MANAGEMENT, L.P. Increases Stake in 89bio Inc - GuruFocus.com
Major Investment Alert: 89bio Stock Sees Multi-Million Dollar Boost! - TipRanks
Leerink raises 89bio stock target to $37 on NASH study optimism - Investing.com Canada
89bio Inc [ETNB] Insider Activity: An Update for Investors - Knox Daily
89bio Closes $287.5 Million Public Offering -February 03, 2025 at 11:17 am EST - Marketscreener.com
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
89bio Secures Massive $287.5M Capital Injection: What This Means for NASH Treatment Future - StockTitan
89bio (NASDAQ:ETNB) Stock Price Up 8.3%Here's What Happened - MarketBeat
89bio (NASDAQ:ETNB) Shares Gap UpHere's Why - MarketBeat
89bio (NASDAQ:ETNB) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
89bio's SWOT analysis: pegozafermin's potential in MASH and SHTG markets - Investing.com
89bio Inc (ETNB) Offers An Excellent Investment Opportunity At Current Levels - Stocks Register
89bio’s Pegozafermin Is Now Gaining Momentum (NASDAQ:ETNB) - Seeking Alpha
MASH momentum prompts $250 million raise for 89bio - The Pharma Letter
89bio Prices $250 Million Offering of Stock, Warrants -January 29, 2025 at 04:48 am EST - Marketscreener.com
89bio, Inc. (NASDAQ:ETNB) Receives $30.33 Average Target Price from Brokerages - Defense World
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
89bio Secures Quarter-Billion Dollar War Chest: Major Financial Institutions Back Massive Capital Raise - StockTitan
Why 89bio Stock Lagged the Market Today - MSN
Why 89bio (ETNB) Stock Is Moving Today - GuruFocus.com
Investors Purchase High Volume of Call Options on 89bio (NASDAQ:ETNB) - Defense World
After-hours movers: Nucor, Graco, 89bio Inc - Investing.com India
89bio seeks $250 million in public stock offering By Investing.com - Investing.com Nigeria
89bio seeks $250 million in public stock offering - MSN
89bio stock falls following public offering announcement - MSN
89bio stock rallies 40% amid data for rival MASH drug - MSN
89bio Launches $250 Million Securities Offering -- Shares Down After Hours -January 27, 2025 at 05:48 pm EST - Marketscreener.com
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):